x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Beyond Biotech - the podcast from Labiotech

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what"s happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

news tech news

All Episodes

46:26

Alex Telford on AI, drug discovery, digital twins,...

Beyond Biotech - the podcast from Labiotech ·

2025/06/13

What are the most interesting questions in biotech, and is it even possible to find answers to those questions? Alex Telford is the co-founder of Convoke and a biotech blogger from the San Francisco Bay Area. His blog post, 'Some questions about biotech that I find interesting' provoked conversations online as readers engaged with questions about topics as diverse as the impacts of regulation, the role of serendipity in drug discovery, clinical trial failure rates, and the best structure for ...

en-us

42:12

Corporate venture capital and biotechnology in 2025:...

Beyond Biotech - the podcast from Labiotech ·

2025/06/06

When biotechs start fundraising they regularly turn to the venture capital market seeking investment. The pool of VC money can be large, and part of that pool is corporate venture capital. Backed by firms keen to identify the next big thing in biotechnology, corporate VC money can be an attractive way for biotechs to raise funds privately while benefiting from the support and expertise of corporate supporters. This week I talked with Paolo Di Giorgio and Regina Hodits of Angelini Ventures, th...

en-us

39:27

The state of biotech finance and fundraising in Q2...

Beyond Biotech - the podcast from Labiotech ·

2025/05/30

Biotechnology has always been a dynamic domain, but the world of finance that provides the fuel for the fire is just as vibrant. Trying to predict where the market for biotech investment is heading is always risky but for experts like Baker McKenzie’s Roel Meers, understanding where the market is moving is where he eats. I spoke to Roel this week to unpack just where biotech funding stands in Q2 2025, to get a feel for the sorts of M&As, IPOs, and licensing deals we should be looking for ...

en-us

35:00

How generative AI and 'Photoshop for proteins' are...

Beyond Biotech - the podcast from Labiotech ·

2025/05/23

Generative artificial intelligence (GenAI) is already changing how people research, communicate, and interact, but its biggest impacts on biotech are still to come. Cradle is a Dutch-Swiss biotech startup founded in 2021 that has developed a web-based software platform leveraging GenAI to accelerate protein design and optimization, aiding scientists in biotechnology R&D. Cradle’s technology integrates AI with wet lab experimentation, doubling the speed of most projects compared to industr...

en-us

33:52

Fighting mucopolysaccharidosis type I, a rare...

Beyond Biotech - the podcast from Labiotech ·

2025/05/16

There are cell therapies, gene therapies, and biologics – and then there is Immusoft. Immusoft sits at the nexus point of some of the most innovative approaches in biopharma, and their Immune System Programming platform is unique in its capacity to address the rare disease, MPS I. This week we talk with Immusoft CEO Sean Ainsworth to learn more about his journey in biotechnology, the work that Immusoft is doing in B-cell reprogramming and unpack some of the positive results that t...

en-us

44:25

Inside Flagship Pioneering's strategy: How this VC...

Beyond Biotech - the podcast from Labiotech ·

2025/05/09

Flagship Pioneering doesn't go out to find the next big thing in biotech when investing their billions in fund capital - instead, they take a different route. Flagship Pioneering has founded more than 100 companies in the life sciences worth in total an estimated $75 billion. With a proven model for biotech startup success and a culture designed to surface new and interesting ideas, Flagship offers a different approach to biotech funding that is paying off time and again. In this episode I ta...

en-us

34:00

TCR-NK: A novel cell therapy transforming cancer...

Beyond Biotech - the podcast from Labiotech ·

2025/05/02

Are TCR-NK treatments the next big thing in cell therapies for cancer patients? As biotechs and pharma companies continue to innovate to address patient needs in oncology, T-cell receptor therapies, or TCR-Ts, are attracting significant interest and investment. There are already some promising results for TCR-Ts tackling solid tumors – but one Norwegian biotech is taking a slightly different track. This week, we sit down with Namir Hassan, CEO of Zelluna, a company with a mission to eliminate...

en-us

39:40

AI in biotech today, and how it will impact the...

Beyond Biotech - the podcast from Labiotech ·

2025/04/25

AI is driving innovation across industries, including biotech, but where is its influence felt most and what opportunities for future impact are emerging? David del Bourgo is the co-founder and CEO of WhiteLab Genomics, an innovative biotech that is leveraging the power of AI to accelerate drug discovery and development from its Paris, Boston, and Montreal bases. In this episode he explains how WhiteLab uses AI technologies to identify targets and engineer vectors, but also offers a wider vie...

en-us

41:13

How nanobodies will revolutionize immunotherapy

Beyond Biotech - the podcast from Labiotech ·

2025/04/11

From llamas and camels to humans worldwide. Nanobodies are enjoying success in the clinic and experts are hailing these camelid-derived biologics as one of the next big things in immunotherapy. Kristian Reich is co-founder and CSO of MoonLake Immunotherapeutics. After a long and distinguished career as a clinician and researcher, Kristian helped to launch MoonLake in 2021 and quickly helped move their lead candidate to the clinic. Now, on the verge of Phase III trials, he joins 'Beyond Biotec...

en-us

39:38

Meeting the global demand for cell therapies: scaling...

Beyond Biotech - the podcast from Labiotech ·

2025/04/04

Cell therapies are at the cutting edge of personalized medicine but as demand for these therapies grows, how will the industry scale manufacturing to meet patient needs? Fabian Gerlinghaus is co-founder and CEO of Cellares. He and his team have developed the Cell Shuttle, an advanced cell manufacturing technology that is already demonstrating the potential to 10x cell yields while halving costs for pharmaceuticals companies and innovators. Is this the future for smart cell manufacturing? 0:52...

en-us

33:48

Treating spinal cord injuries with stem cells

Beyond Biotech - the podcast from Labiotech ·

2025/03/28

Spinal cord injuries impact millions of people worldwide and, unlike many chronic injuries, they usually arrive with no forewarning, impacting the young and old alike. Brian Culley is CEO of Lineage Cell Therapeutics and his company is now in the clinic with a stem cell therapy for spinal cord injuries. Learn why stem cells could be promising for these devastating injuries and how Brian and his team plan to overcome the challenges of manufacturing at scale and succeeding in a highly regulated...

en-us

37:47

Are mitochondrial therapeutics about to go mainstream?

Beyond Biotech - the podcast from Labiotech ·

2025/03/21

Mitochondria are famously the powerhouse of the cell, but will mitochondrial therapeutics power the next big mainstream medical breakthrough? Klaus Dugi is CEO of Vandria, a biotech that develops mitophagy inducers that rejuvenate cells to treat age-related and chronic diseases. He joins 'Beyond Biotech' to talk cell mitophagy, biotech agility, and innovation in tackling neurodegenerative disease. 00:42 Introducing Klaus Dugi 02:51 Lessons learned in top pharma 05:10...

en-us

41:51

Fighting Alzheimer's with innovative stem cell therapies

Beyond Biotech - the podcast from Labiotech ·

2025/03/14

Regeneration Biomedical has developed a new technique to address neurodegenerative diseases like Alzheimer's using stem cell therapy. Dr. Christopher Duma, has long been an innovator in neurosurgery using a gamma knife radiosurgery to treat glioblastoma. Now with Regeneration Biomedical, Duma is taking on neurodegenerative diseases with a first-in-human clinical trial where a patient's own stem cells are injected directly into their brain. On the podcast this week, we talk with Duma about his...

en-us

28:53

[Rebroadcast] How AI immune system mapping can boost...

Beyond Biotech - the podcast from Labiotech ·

2025/03/07

We’re taking a short break this week and, while we’re away, we invite you to enjoy one of our favorite episodes. We will return with a brand-new episode next week! Immunai is mapping the immune system at unprecedented scale and granularity. The map, paired with machine learning, looks at how the immune system will respond to drug targets, offering an affordable way to prevent expensive drug failures. The ultimate goal is to market immune treatments for diseases like cancer faster than e...

en-us

26:42

The TCR-T cell therapies of tomorrow

Beyond Biotech - the podcast from Labiotech ·

2025/02/28

Sweden's fastest growing private biotech, Anocca, is making plans for clinical trials in pancreatic cancer, with the TCR-T cell therapy trials called VIDAR-1. The CEO, Reagan Jarvis, when a researcher, pitched the company idea to a leading Swedish industrialist, who became co-founder, and provided the initial financing. The company has raised more than €100m to date. On the podcast this week, we have a conversation with Jarvis about TCR-T cell therapies, creating off-the-shelf products ...

en-us

29:56

Can RNA drugs solve the obesity epidemic?

Beyond Biotech - the podcast from Labiotech ·

2025/02/21

Resalis Therapeutics is pursuing a groundbreaking approach to obesity treatment. Unlike current therapies that primarily focus on appetite suppression, Resalis’ lead program, RES-010, is a non-coding RNA drug candidate that targets underlying biological pathways to promote sustainable weight loss. By enhancing energy expenditure through white-to-brown adipose tissue conversion while preserving muscle mass, RES-010 is positioned as an ideal standalone therapy or a synergistic option for ...

en-us

21:24

Reversing cancer mechanisms to fight back against...

Beyond Biotech - the podcast from Labiotech ·

2025/02/14

CatalYm is preparing to initiate its broad phase 2b clinical development program for visugromab to tackle multiple solid tumor indications. Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15 (GDF-15), a locally acting immunosuppressant fostering immunotherapy resistance. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by reenabling immune cell activation...

en-us

32:32

Targeting the dark genome to develop new therapies to...

Beyond Biotech - the podcast from Labiotech ·

2025/02/07

In the fall of 2024, Haya Therapeutics, based in Switzerland and San Diego, landed a $1bn deal with Eli Lilly to apply its long non-coding RNA (ncRNA) technology to obesity. The company’s lead candidate, HTX-001, is making progress towards the clinic in cardiomyopathy. CEO Samir is one of the first researchers to publish on lncRNA – which is also known as the Dark Genome This week, our podcast guest is Samir Ounzain, CEO and co-founder of Haya Therapeutics. Ounzain was one of the first resear...

en-us

31:22

Can Tumor Activated Therapy kill solid tumors?

Beyond Biotech - the podcast from Labiotech ·

2025/01/31

Solid tumors present a big challenge for current treatments. However, a new approach might provide the answers - Tumor Activated Therapy. By targeting specific proteins common in all solid tumor micro-environments, Seekyo scientists think this can induce self-destruction of the tumor itself. Seekyo’s lead therapy, SKY01, can only be activated within the tumor, making it a highly-targeted solution.This differentiated approach overcomes the limits of existing treatments, such as small mole...

en-us

19:57

J.P. Morgan Annual Healthcare Conference 2025: trends...

Beyond Biotech - the podcast from Labiotech ·

2025/01/24

This week, we take a look at some of the highlights from the 43rd Annual J.P. Morgan Healthcare Conference, which took place in San Francisco recently.While there weren’t necessarily many financial blockbusters, there were plenty of announcements and discussions on everything from artificial intelligence to the rising influence of Chinese companies and research, to the potential ramifications of the incoming Trump administration in the U.S.To help us navigate some of the highlights of the eve...

en-us

171 results

Similar Podcasts

Expres Ráno

Expres FM

PBS News Hour - Full Show

PBS NewsHour

CD Voice

China Daily

Israel Today: Ongoing War Report

Noa Levi

Jeffrey Epstein: The Coverup Chronicles

Bobby Capucci